What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Internal medicine, Multiple myeloma, Surgery, Transplantation and Gastroenterology are his primary areas of study.
His research investigates the connection between Internal medicine and topics such as Oncology that intersect with issues in Newly diagnosed.
His Multiple myeloma study deals with the bigger picture of Immunology.
Many of his research projects under Surgery are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His Hematopoietic stem cell transplantation study, which is part of a larger body of work in Transplantation, is frequently linked to Plerixafor, bridging the gap between disciplines.
His study explores the link between Lenalidomide and topics such as Bortezomib that cross with problems in Regimen.
His most cited work include:
- Improved survival in multiple myeloma and the impact of novel therapies (1718 citations)
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (768 citations)
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (570 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Multiple myeloma, Surgery, Oncology and Gastroenterology.
His Internal medicine and Lenalidomide, Transplantation, Amyloidosis, Autologous stem-cell transplantation and AL amyloidosis investigations all form part of his Internal medicine research activities.
His Amyloidosis research integrates issues from Immunoglobulin light chain, Hematologic Response, Chemotherapy and Immunoglobulin Light-chain Amyloidosis.
Francis K. Buadi works mostly in the field of Multiple myeloma, limiting it down to topics relating to Dexamethasone and, in certain cases, Cyclophosphamide.
His work on Progression-free survival as part of general Oncology research is often related to In patient, thus linking different fields of science.
His research integrates issues of Survival rate, Bone marrow and Very Good Partial Response in his study of Gastroenterology.
He most often published in these fields:
- Internal medicine (70.31%)
- Multiple myeloma (55.81%)
- Surgery (30.23%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (70.31%)
- Multiple myeloma (55.81%)
- Oncology (27.22%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Multiple myeloma, Oncology, Amyloidosis and AL amyloidosis.
Internal medicine connects with themes related to Gastroenterology in his study.
His research in Multiple myeloma intersects with topics in Retrospective cohort study, Newly diagnosed, Bone marrow and Hematopoietic stem cell transplantation.
His Oncology research focuses on Lenalidomide and how it connects with Bortezomib.
Francis K. Buadi has researched Amyloidosis in several fields, including Immunoglobulin light chain, Hematologic Response, Stage and Very Good Partial Response.
His AL amyloidosis study incorporates themes from Cancer research, Chromosomal translocation, Urology, Venetoclax and Proteinuria.
Between 2018 and 2021, his most popular works were:
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial (84 citations)
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. (52 citations)
- Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis (46 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
Francis K. Buadi mainly focuses on Internal medicine, Multiple myeloma, AL amyloidosis, Gastroenterology and Oncology.
His multidisciplinary approach integrates Internal medicine and In patient in his work.
His Multiple myeloma research is multidisciplinary, incorporating elements of Anemia, Retrospective cohort study, Stem cell, Monoclonal protein and Transplantation.
His AL amyloidosis study integrates concerns from other disciplines, such as Interquartile range, Urology, Minimal residual disease, Kidney and Amyloidosis.
The study incorporates disciplines such as Odds ratio, Renal function, Multivariate analysis, Confidence interval and Bone marrow in addition to Gastroenterology.
In his research on the topic of Oncology, Standard of care is strongly related with Lenalidomide.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
